Listen
Reason for request
Inclusion on list of medicines refundable by National Health Insurance and approved for hospital use in the extension of indication “Treatment of schizophrenia in adolescents aged 15 years and older”.
-
Clinical Benefit
| Substantial |
The actual benefit of these proprietary medicinal products in the extension of indication is substantial. |
Clinical Added Value
| no clinical added value |
Given the absence of a comparison with an active comparator and the inadequate duration of evaluation, and pending the availability of controlled data over a treatment period of at least 6 months, ABILIFY does not provide an improvement in actual benefit in the management of schizophrenia in adolescents. |
English version
Contact Us
Évaluation des médicaments
